Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

M.D. Anderson Cancer Center, Houston, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, TX
Treatments:ChemotherapyHospital:M.D. Anderson Cancer Center
Drugs:Journal:Link
Date:Jun 2014

Description:

Patients:
This phase 2 study involved previously treated, persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma patients who were divided into two separate treatment groups. Group A consisted of 66 patients with a median age of 61.7 years. Group B had 63 patients with a median age of 61.9 years.

Treatment:
Patients in group A received chemotherapy with docetaxel.

Patients in group B were treated with the chemotherapy agent docetaxel and the biologic therapy agent vandetanib, a kinase inhibitor that interferes with tumor growth.

Toxicities:
The most severe toxicities in group A were grade 4 and included leukocytosis (increased white blood cell count) and neutropenia.

There was one treatment-related death in group B due to myelosuppression (decreased blood cell count). Grade 4 neutropenia and grade 3 fatigue and rash were also reported.

Results:
The median overall survival rates for groups A and B were 18 and 14 months, respectively.

Support:
This study was partially supported by AstraZeneca, makers of vandetanib.

Correspondence: Dr. Robert L. Coleman; email: [email protected]



Back